Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
As CVS Health and Aetna are awaiting final regulatory approval for their $69 billion merger, Aetna, the nation’s third-largest health insurance provider, reported strong earnings during the third quarter of the year, with $1 billion income.
Under the threat of potentially losing its contracts with a major insurance provider, post-acute care provider Envision Healthcare has launched a second information campaign called “We Care.”
As healthcare prices and prescription drug costs continue to soar in the United States, one insurer in Utah is taking an innovative approach to reducing costs—by offering to pay its enrollees to fill prescription medications in Mexico, The Salt Lake Tribune reported.
A company that uses artificial intelligence (AI) to find healthcare data has raised millions in funding in a push to grow the business, according to a report by VentureBeat.
A deep-learning (DL) algorithm was able to assess mammographic breast density at the level of an experienced mammographer, according to a study published in Radiology.
Nearly 90 percent of hospitals are able to electronically share patient records with outside sources, according to the latest analysis by the Office of the National Coordinator (ONC) for Health Information Technology.
The American College of Cardiology has sent a letter to HHS Secretary Robert F. Kennedy Jr. that outlines some of the organization’s central priorities and concerns.
If the Trump administration continues taking a laissez-faire stance toward AI—including AI used in healthcare—why not let the states go it alone on regulating the technology?
